Syntellix obtains product approval for India
On October 07, 2021, Syntellix obtained the license to bring five different product families of its revolutionary bioabsorbable magnesium-based implants to market from India's Central Drugs Standard Control Organisation (CDSCO) for the Indian market. With this approval, the company's global market access and the number of potential patients treated with the company's MAGNEZIX® implants have expanded by 1.38 billion, bringing the total number of people who can be treated with the company's MAGNEZIX® implants to 3.8 billion.
According to DelveInsight’s Orthopedic Digit Implants Market Analysis, India is expected t...
